AIMS: To investigate the changes of expression and methylation status of PRDM2, PRDM5, PRDM16 in lung cancer cells after treatment with demethylation agent. METHODS: A549 (lung adenocarcinoma cell line), HTB-182 (lung squamous cell carcinoma cell line) and HBE (normal bronchial cell line) were treated with 5-aza-2dC. The methylation state of PRDM2, PRDM5, PRDM16 was detected by MSP. The expression of PRDM2, PRDM5, PRDM16 was detected by RT-PCR and Western blot analysis. Cell growth was detected by MTT assay. RESULTS: 5-aza-2-dC reduced the methylation of PRDM2, PRDM5, PRDM16 gene in A549 and HTB-182 cells but not in HBE cells. Consistently, 5-aza-2dC increased mRNA and protein expression of PRDM2, PRDM5, PRDM16 in A549 and HTB-182 cells but not in HBE cells. Furthermore, 5-aza-2dC inhibited the growth of A549 and HTB-182 cells but not HBE cells. CONCLUSIONS: PRDM2, PRDM5, PRDM16 promoters are methylated and their expression is suppressed in lung cancer cells. Demethylation drug 5-aza-2dC could upregulate the expression of PRDM2, PRDM5, PRDM16 and suppress lung cancer cell growth. 5-aza-2dC has potential to be used for lung cancer therapy by epigenetic mechanism.
AIMS: To investigate the changes of expression and methylation status of PRDM2, PRDM5, PRDM16 in lung cancer cells after treatment with demethylation agent. METHODS: A549 (lung adenocarcinoma cell line), HTB-182 (lung squamous cell carcinoma cell line) and HBE (normal bronchial cell line) were treated with 5-aza-2dC. The methylation state of PRDM2, PRDM5, PRDM16 was detected by MSP. The expression of PRDM2, PRDM5, PRDM16 was detected by RT-PCR and Western blot analysis. Cell growth was detected by MTT assay. RESULTS:5-aza-2-dC reduced the methylation of PRDM2, PRDM5, PRDM16 gene in A549 and HTB-182 cells but not in HBE cells. Consistently, 5-aza-2dC increased mRNA and protein expression of PRDM2, PRDM5, PRDM16 in A549 and HTB-182 cells but not in HBE cells. Furthermore, 5-aza-2dC inhibited the growth of A549 and HTB-182 cells but not HBE cells. CONCLUSIONS:PRDM2, PRDM5, PRDM16 promoters are methylated and their expression is suppressed in lung cancer cells. Demethylation drug 5-aza-2dC could upregulate the expression of PRDM2, PRDM5, PRDM16 and suppress lung cancer cell growth. 5-aza-2dC has potential to be used for lung cancer therapy by epigenetic mechanism.
Authors: Xing-sheng Shu; Hua Geng; Lili Li; Jianming Ying; Chunhong Ma; Yajun Wang; Fan Fong Poon; Xian Wang; Ying Ying; Winnie Yeo; Gopesh Srivastava; Sai Wah Tsao; Jun Yu; Joseph J Y Sung; Shi Huang; Anthony T C Chan; Qian Tao Journal: PLoS One Date: 2011-11-08 Impact factor: 3.240
Authors: Lyndsey E Shorey-Kendrick; Cindy T McEvoy; Betsy Ferguson; Julja Burchard; Byung S Park; Lina Gao; Brittany H Vuylsteke; Kristin F Milner; Cynthia D Morris; Eliot R Spindel Journal: Am J Respir Crit Care Med Date: 2017-09-15 Impact factor: 21.405
Authors: Bo Zhou; Jingya Wang; Shirley Y Lee; Jie Xiong; Natarajan Bhanu; Qi Guo; Peilin Ma; Yuqing Sun; Rajesh C Rao; Benjamin A Garcia; Jay L Hess; Yali Dou Journal: Mol Cell Date: 2016-04-14 Impact factor: 17.970
Authors: Qiyuan Yang; Xingwei Liang; Xiaofei Sun; Lupei Zhang; Xing Fu; Carl J Rogers; Anna Berim; Shuming Zhang; Songbo Wang; Bo Wang; Marc Foretz; Benoit Viollet; David R Gang; Buel D Rodgers; Mei-Jun Zhu; Min Du Journal: Cell Metab Date: 2016-09-15 Impact factor: 27.287
Authors: Zachary R Hunter; Lian Xu; Guang Yang; Nicholas Tsakmaklis; Josephine M Vos; Xia Liu; Jie Chen; Robert J Manning; Jiaji G Chen; Philip Brodsky; Christopher J Patterson; Joshua Gustine; Toni Dubeau; Jorge J Castillo; Kenneth C Anderson; Nikhil M Munshi; Steven P Treon Journal: Blood Date: 2016-06-14 Impact factor: 22.113
Authors: Kostadin Rolev; Dominic G O'Donovan; Christiana Georgiou; Madhavan S Rajan; Alexandra Chittka Journal: Exp Eye Res Date: 2017-02-20 Impact factor: 3.467